AI CEOs Urge Congress to Mandate DNA Screening

A group of prominent AI leaders, including Sam Altman, Dario Amodei, Demis Hassabis, and Mustafa Suleyman, signed an open letter calling on Congress to mandate screening and recordkeeping for synthetic DNA and RNA orders. The letter, organized by the Foundation for American Innovation and the Institute for Progress and posted at screendna.org, asks providers of synthetic nucleic acids to verify who is ordering, screen the sequences themselves, and keep records of transactions.

The signatories warn that rapidly improving AI could erode the knowledge barriers that have historically kept biological-weapons capability out of reach for most actors, even as the same tools advance medicine and science. Framing screening as a comparatively low-cost safeguard, they argue mandatory requirements would standardize practices that today are voluntary and unevenly applied.

Coverage by the Wall Street Journal, Fortune, and Quartz emphasizes that rival executives, who have publicly clashed on other issues, aligned here. That unusual consensus raises the political salience of the proposal and makes legislative or regulatory action more plausible.

For teams working at the AI-biology interface, mandatory screening would change vendor obligations and procurement, push for updated technical standards and automated sequence-screening tools, and introduce privacy and export-control questions for cross-border collaboration. The letter targets the synthesis supply chain specifically, rather than model capabilities, as the most actionable control point.